iRadimed (IRMD)
Market Price (10/12/2026): $87.42 | Market Cap: $1.1 BilSector: Health Care | Industry: Life Sciences Tools & Services
iRadimed (IRMD)
Market Price (10/12/2026): $87.42Market Cap: $1.1 BilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 32% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 31%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 28% Low stock price volatilityVol 12M is 31% Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Medical Technology & Healthcare Infrastructure. Themes include MRI-Compatible Patient Monitoring, and MRI-Compatible Medical Devices. | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 41x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 41x, P/EPrice/Earnings or Price/(Net Income) is 48x Key risksIRMD key risks include [1] a significant reliance on a limited product portfolio and [2] the vulnerability of its near-monopoly market position to new competition. |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 32% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 31%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 28% |
| Low stock price volatilityVol 12M is 31% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine, and Medical Technology & Healthcare Infrastructure. Themes include MRI-Compatible Patient Monitoring, and MRI-Compatible Medical Devices. |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 41x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 41x, P/EPrice/Earnings or Price/(Net Income) is 48x |
| Key risksIRMD key risks include [1] a significant reliance on a limited product portfolio and [2] the vulnerability of its near-monopoly market position to new competition. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 10/1/2026
iRadimed (IRMD) stock has lost about 10% since 6/30/2026 because of the following key factors:
iRadimed (IRMD) stock experienced an approximate 10% decline during the period from late fiscal Q2 2026 through fiscal Q3 2026, specifically seeing a 9.99% decrease over three months. This trend was primarily driven by a combination of market sentiment regarding its valuation, nuanced earnings details despite beats, and transitional costs associated with a new product launch.
1. Analyst downgrades and valuation concerns.
In late fiscal Q3 2026, iRadimed faced increased scrutiny from analysts regarding its valuation. Needham & Company LLC initiated coverage on September 22, 2026, with a "Hold" rating, explicitly citing "valuation concerns" due to the stock trading at a high price-to-earnings (P/E) ratio of 46.21 and an enterprise value-to-EBITDA (EV/EBITDA) multiple of 34.11, suggesting it was overvalued. This followed a downgrade by Wall Street Zen from "buy" to "hold" on August 8, 2026. These analyst sentiments indicated that the company's growth potential might already be priced into the stock, leading some to recommend waiting for a more favorable entry point.
2. Mixed signals from fiscal Q2 2026 earnings despite beating estimates.
iRadimed reported its fiscal Q2 2026 earnings on July 31, 2026, beating consensus estimates with an EPS of $0.46 against an expected $0.44 and revenue of $20.47 million versus an estimated $20.35 million. However, the earnings call highlighted "margin compression and higher costs from the initial production ramp" of its next-generation 3870 MRI-compatible IV infusion pump, along with a "modest decline in quarterly net income and gross margin" compared to the prior year. While the company reaffirmed its full-year 2026 guidance for revenue of $91.0 million to $96.0 million and GAAP diluted EPS of $1.90 to $2.05, these underlying cost pressures likely introduced investor caution.
Show more
iRadimed (IRMD) stock has lost about 10% since 6/30/2026 because of the following key factors:
iRadimed (IRMD) stock experienced an approximate 10% decline during the period from late fiscal Q2 2026 through fiscal Q3 2026, specifically seeing a 9.99% decrease over three months. This trend was primarily driven by a combination of market sentiment regarding its valuation, nuanced earnings details despite beats, and transitional costs associated with a new product launch.
1. Analyst downgrades and valuation concerns.
In late fiscal Q3 2026, iRadimed faced increased scrutiny from analysts regarding its valuation. Needham & Company LLC initiated coverage on September 22, 2026, with a "Hold" rating, explicitly citing "valuation concerns" due to the stock trading at a high price-to-earnings (P/E) ratio of 46.21 and an enterprise value-to-EBITDA (EV/EBITDA) multiple of 34.11, suggesting it was overvalued. This followed a downgrade by Wall Street Zen from "buy" to "hold" on August 8, 2026. These analyst sentiments indicated that the company's growth potential might already be priced into the stock, leading some to recommend waiting for a more favorable entry point.
2. Mixed signals from fiscal Q2 2026 earnings despite beating estimates.
iRadimed reported its fiscal Q2 2026 earnings on July 31, 2026, beating consensus estimates with an EPS of $0.46 against an expected $0.44 and revenue of $20.47 million versus an estimated $20.35 million. However, the earnings call highlighted "margin compression and higher costs from the initial production ramp" of its next-generation 3870 MRI-compatible IV infusion pump, along with a "modest decline in quarterly net income and gross margin" compared to the prior year. While the company reaffirmed its full-year 2026 guidance for revenue of $91.0 million to $96.0 million and GAAP diluted EPS of $1.90 to $2.05, these underlying cost pressures likely introduced investor caution.
Show more
Updated on 10/1/2026
iRadimed (IRMD) stock has lost about 10% since 6/30/2026 because of the following key factors:
iRadimed (IRMD) stock experienced an approximate 10% decline during the period from late fiscal Q2 2026 through fiscal Q3 2026, specifically seeing a 9.99% decrease over three months. This trend was primarily driven by a combination of market sentiment regarding its valuation, nuanced earnings details despite beats, and transitional costs associated with a new product launch.
1. Analyst downgrades and valuation concerns.
In late fiscal Q3 2026, iRadimed faced increased scrutiny from analysts regarding its valuation. Needham & Company LLC initiated coverage on September 22, 2026, with a "Hold" rating, explicitly citing "valuation concerns" due to the stock trading at a high price-to-earnings (P/E) ratio of 46.21 and an enterprise value-to-EBITDA (EV/EBITDA) multiple of 34.11, suggesting it was overvalued. This followed a downgrade by Wall Street Zen from "buy" to "hold" on August 8, 2026. These analyst sentiments indicated that the company's growth potential might already be priced into the stock, leading some to recommend waiting for a more favorable entry point.
2. Mixed signals from fiscal Q2 2026 earnings despite beating estimates.
iRadimed reported its fiscal Q2 2026 earnings on July 31, 2026, beating consensus estimates with an EPS of $0.46 against an expected $0.44 and revenue of $20.47 million versus an estimated $20.35 million. However, the earnings call highlighted "margin compression and higher costs from the initial production ramp" of its next-generation 3870 MRI-compatible IV infusion pump, along with a "modest decline in quarterly net income and gross margin" compared to the prior year. While the company reaffirmed its full-year 2026 guidance for revenue of $91.0 million to $96.0 million and GAAP diluted EPS of $1.90 to $2.05, these underlying cost pressures likely introduced investor caution.
3. Near-term margin pressure due to new product transition.
The ongoing transition to the next-generation 3870 MRI-compatible IV infusion pump, while a significant long-term opportunity estimated at $300 million, created short-term headwinds. The company acknowledged that this product transition impacted margins and revenue growth in fiscal Q2 2026. Although the 3870 pump saw a successful initial launch and strong bookings, the associated production ramp-up led to higher costs and a modest decline in gross margin to 74% in fiscal Q2 2026, compared to a 75% year-to-date margin. These increased operational expenses dampened immediate profitability, despite positive long-term prospects for the new platform.
Show less
iRadimed (IRMD) stock has lost about 10% since 6/30/2026 because of the following key factors:
iRadimed (IRMD) stock experienced an approximate 10% decline during the period from late fiscal Q2 2026 through fiscal Q3 2026, specifically seeing a 9.99% decrease over three months. This trend was primarily driven by a combination of market sentiment regarding its valuation, nuanced earnings details despite beats, and transitional costs associated with a new product launch.
1. Analyst downgrades and valuation concerns.
In late fiscal Q3 2026, iRadimed faced increased scrutiny from analysts regarding its valuation. Needham & Company LLC initiated coverage on September 22, 2026, with a "Hold" rating, explicitly citing "valuation concerns" due to the stock trading at a high price-to-earnings (P/E) ratio of 46.21 and an enterprise value-to-EBITDA (EV/EBITDA) multiple of 34.11, suggesting it was overvalued. This followed a downgrade by Wall Street Zen from "buy" to "hold" on August 8, 2026. These analyst sentiments indicated that the company's growth potential might already be priced into the stock, leading some to recommend waiting for a more favorable entry point.
2. Mixed signals from fiscal Q2 2026 earnings despite beating estimates.
iRadimed reported its fiscal Q2 2026 earnings on July 31, 2026, beating consensus estimates with an EPS of $0.46 against an expected $0.44 and revenue of $20.47 million versus an estimated $20.35 million. However, the earnings call highlighted "margin compression and higher costs from the initial production ramp" of its next-generation 3870 MRI-compatible IV infusion pump, along with a "modest decline in quarterly net income and gross margin" compared to the prior year. While the company reaffirmed its full-year 2026 guidance for revenue of $91.0 million to $96.0 million and GAAP diluted EPS of $1.90 to $2.05, these underlying cost pressures likely introduced investor caution.
3. Near-term margin pressure due to new product transition.
The ongoing transition to the next-generation 3870 MRI-compatible IV infusion pump, while a significant long-term opportunity estimated at $300 million, created short-term headwinds. The company acknowledged that this product transition impacted margins and revenue growth in fiscal Q2 2026. Although the 3870 pump saw a successful initial launch and strong bookings, the associated production ramp-up led to higher costs and a modest decline in gross margin to 74% in fiscal Q2 2026, compared to a 75% year-to-date margin. These increased operational expenses dampened immediate profitability, despite positive long-term prospects for the new platform.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -8.3% change in IRMD stock from 6/30/2026 to 10/11/2026 was primarily driven by a -6.1% change in the company's P/E Multiple.| (LTM values as of) | 6302026 | 10112026 | Change |
|---|---|---|---|
| Stock Price ($) | 95.34 | 87.45 | -8.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 86 | 86 | 0.1% |
| Net Income Margin (%) | 27.4% | 26.7% | -2.4% |
| P/E Multiple | 51.6 | 48.5 | -6.1% |
| Shares Outstanding (Mil) | 13 | 13 | 0.0% |
| Cumulative Contribution | -8.3% |
Market Drivers
6/30/2026 to 10/11/2026| Return | Correlation | |
|---|---|---|
| IRMD | -8.3% | |
| Market (SPY) | 4.3% | 11.6% |
| Sector (XLV) | 7.7% | 32.9% |
Fundamental Drivers
The -8.7% change in IRMD stock from 3/31/2026 to 10/11/2026 was primarily driven by a -10.7% change in the company's P/E Multiple.| (LTM values as of) | 3312026 | 10112026 | Change |
|---|---|---|---|
| Stock Price ($) | 95.82 | 87.45 | -8.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 84 | 86 | 3.0% |
| Net Income Margin (%) | 26.8% | 26.7% | -0.4% |
| P/E Multiple | 54.3 | 48.5 | -10.7% |
| Shares Outstanding (Mil) | 13 | 13 | -0.4% |
| Cumulative Contribution | -8.7% |
Market Drivers
3/31/2026 to 10/11/2026| Return | Correlation | |
|---|---|---|
| IRMD | -8.7% | |
| Market (SPY) | 20.0% | 18.9% |
| Sector (XLV) | 17.0% | 31.9% |
Fundamental Drivers
The 24.6% change in IRMD stock from 9/30/2025 to 10/11/2026 was primarily driven by a 12.2% change in the company's P/E Multiple.| (LTM values as of) | 9302025 | 10112026 | Change |
|---|---|---|---|
| Stock Price ($) | 70.19 | 87.45 | 24.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 78 | 86 | 11.2% |
| Net Income Margin (%) | 26.6% | 26.7% | 0.4% |
| P/E Multiple | 43.2 | 48.5 | 12.2% |
| Shares Outstanding (Mil) | 13 | 13 | -0.5% |
| Cumulative Contribution | 24.6% |
Market Drivers
9/30/2025 to 10/11/2026| Return | Correlation | |
|---|---|---|
| IRMD | 24.6% | |
| Market (SPY) | 17.8% | 24.1% |
| Sector (XLV) | 24.3% | 23.1% |
Fundamental Drivers
The 106.4% change in IRMD stock from 9/30/2023 to 10/11/2026 was primarily driven by a 44.2% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 9302023 | 10112026 | Change |
|---|---|---|---|
| Stock Price ($) | 42.38 | 87.45 | 106.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 60 | 86 | 44.2% |
| Net Income Margin (%) | 24.5% | 26.7% | 8.9% |
| P/E Multiple | 36.3 | 48.5 | 33.4% |
| Shares Outstanding (Mil) | 13 | 13 | -1.5% |
| Cumulative Contribution | 106.4% |
Market Drivers
9/30/2023 to 10/11/2026| Return | Correlation | |
|---|---|---|
| IRMD | 106.4% | |
| Market (SPY) | 88.4% | 33.4% |
| Sector (XLV) | 38.9% | 27.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| IRMD Return | 103% | -38% | 75% | 17% | 80% | -11% | 315% |
| Peers Return | 0% | -18% | 15% | 1% | 7% | -1% | 1% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 107% |
Monthly Win Rates [3] | |||||||
| IRMD Win Rate | 83% | 33% | 75% | 75% | 58% | 40% | |
| Peers Win Rate | 44% | 44% | 50% | 48% | 57% | 52% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| IRMD Max Drawdown | -14% | -49% | -26% | -15% | -22% | -22% | |
| Peers Max Drawdown | -16% | -31% | -26% | -18% | -31% | -30% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: GEHC, OSIS, MDT, BDX, BAX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 10/9/2026 (YTD)
How Low Can It Go
| Event | IRMD | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -14.0% | -18.8% |
| % Gain to Breakeven | 16.2% | 23.1% |
| Time to Breakeven | 51 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -19.8% | -9.5% |
| % Gain to Breakeven | 24.7% | 10.5% |
| Time to Breakeven | 70 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -42.5% | -24.5% |
| % Gain to Breakeven | 74.0% | 32.4% |
| Time to Breakeven | 203 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -39.1% | -33.7% |
| % Gain to Breakeven | 64.3% | 50.9% |
| Time to Breakeven | 402 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -36.6% | -19.2% |
| % Gain to Breakeven | 57.7% | 23.8% |
| Time to Breakeven | 931 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -54.5% | -3.7% |
| % Gain to Breakeven | 119.9% | 3.9% |
| Time to Breakeven | 390 days | 6 days |
In The Past
iRadimed's stock fell -14.0% during the 2025 US Tariff Shock. Such a loss loss requires a 16.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | IRMD | S&P 500 |
|---|---|---|
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -42.5% | -24.5% |
| % Gain to Breakeven | 74.0% | 32.4% |
| Time to Breakeven | 203 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -39.1% | -33.7% |
| % Gain to Breakeven | 64.3% | 50.9% |
| Time to Breakeven | 402 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -36.6% | -19.2% |
| % Gain to Breakeven | 57.7% | 23.8% |
| Time to Breakeven | 931 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -54.5% | -3.7% |
| % Gain to Breakeven | 119.9% | 3.9% |
| Time to Breakeven | 390 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -44.6% | -12.2% |
| % Gain to Breakeven | 80.5% | 13.9% |
| Time to Breakeven | 915 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -37.5% | -6.8% |
| % Gain to Breakeven | 60.0% | 7.3% |
| Time to Breakeven | 94 days | 15 days |
In The Past
iRadimed's stock fell -14.0% during the 2025 US Tariff Shock. Such a loss loss requires a 16.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About iRadimed (IRMD)
```html
iRadimed (IRMD) is a medical device company that develops, manufactures, and distributes specialized equipment designed to be compatible with Magnetic Resonance Imaging (MRI) environments. The company addresses the unique challenges of patient care during MRI procedures by providing devices that can operate safely and effectively without interfering with the MRI scanner's powerful magnetic fields, which is crucial for maintaining patient safety and image quality.
The company's core product offerings include the MRidium MRI compatible intravenous (IV) infusion pump system, complete with associated disposable IV tubing sets, which enables precise medication delivery during MRI scans. Additionally, iRadimed provides an MRI compatible patient vital signs monitoring system, allowing healthcare professionals to continuously track vital signs while patients are undergoing imaging. Its product portfolio also includes essential accessories such as non-magnetic IV poles, wireless remote displays/controls, and dose error reduction systems, all tailored for the MRI suite.
iRadimed primarily serves a range of healthcare providers that utilize MRI technology. Its main customers include hospitals, acute care facilities, and outpatient imaging centers. These facilities rely on iRadimed's specialized equipment to ensure safe and efficient patient management during MRI diagnostics and treatments, distributing its products through a combination of direct sales representatives and independent distributors.
```AI Analysis | Feedback
- They're like Medtronic or Baxter, but exclusively for MRI-compatible medical devices.
- Think of them as the Philips Healthcare of MRI-safe patient monitoring and IV infusion systems.
AI Analysis | Feedback
- MRidium MRI Compatible IV Infusion Pump System: An intravenous infusion pump system designed to function safely and accurately within the magnetic environment of an MRI scanner.
- MRI Compatible Patient Vital Signs Monitoring System: A system used to monitor critical patient vital signs safely and effectively during MRI procedures.
- Non-Magnetic IV Poles: Intravenous poles constructed from non-magnetic materials to ensure safety and compatibility within MRI environments.
- Wireless Remote Displays/Controls: Components that allow for remote operation and monitoring of medical devices used in MRI settings.
- Side Car Pump Modules: Additional pump modules that can be integrated with existing infusion systems to expand functionality.
- Dose Error Reduction Systems: Technologies implemented to minimize medication errors during intravenous drug administration in medical settings.
- SpO2 Monitoring with Sensors and Accessories: Devices and components for monitoring blood oxygen saturation levels, compatible for use in MRI environments.
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
Roger Susi
FOUNDER, PRESIDENT, AND CEO
Mr. Susi is the founder of iRadimed and has served as a member of the Board since the company's inception. He also founded, served as Chairman, and Chief Executive Officer of Invivo Research Inc., a medical device company and the predecessor to Invivo Corporation, which pioneered MRI-safe patient monitoring. Mr. Susi has over 40 years of management experience in the medical device industry. He resumed his duties as Chief Executive Officer and President of iRadimed in May 2020, having previously held these roles from the company's incorporation until August 2019.
John "Jack" Glenn
CHIEF FINANCIAL OFFICER
Mr. Glenn has served as Chief Financial Officer of iRadimed since 2022. He is a financial executive with over 30 years of experience directing corporate finance activities for both public and private companies. Prior to joining iRadimed, Mr. Glenn served as Chief Financial Officer at Esko Bionics. His extensive experience also includes CFO roles at Sonendo, Armetheon, Solta Medical, Cholestech, and Invivo Corporation. Notably, he assisted Solta Medical in its strategic acquisition by Valeant Pharmaceutical, and was involved when Cholestech was acquired by Alere Medical, and Invivo Corporation was sold to Intermagnetics General Corporation.
Jeffery Chiprin
CHIEF COMMERCIAL OFFICER
Mr. Chiprin has served as iRadimed's Chief Commercial Officer since November 2024, bringing over 30 years of senior leadership experience in medical technology from both private and public sectors. He was previously with Invivo Corporation, joining in 1996 and serving as Vice President of North American Sales for six years. He was part of the leadership team that facilitated the sale of Invivo Corporation to Philips Corporation. Following this, he spent 14 years as Vice President of Sales at Philips Corporation, and later served as Sr. Vice President of Worldwide Sales in private companies specializing in innovative MRI solutions.
Chris Williamson
EXECUTIVE VICE PRESIDENT OF CONTINUOUS IMPROVEMENT AND INFORMATION TECHNOLOGY
Mr. Williamson serves as the Executive Vice President of Continuous Improvement and Information Technology, where he is responsible for leading transformation initiatives aimed at supporting growth, maximizing operational efficiency, and enhancing profitability. He possesses over 20 years of experience in technology, business transformation, and operations within highly regulated industries.
AI Analysis | Feedback
iRadimed Corporation (IRMD) faces several key risks inherent to its specialized niche in MRI-compatible medical devices. These risks primarily stem from its concentrated product portfolio, the demanding regulatory environment, and vulnerabilities within its supply chain.
Key Risks to the Business:
- Dependence on a Limited Product Range: iRadimed's financial performance is significantly reliant on a few core products, mainly its MRidium MRI compatible IV infusion pump systems and the 3880 MRI compatible patient vital signs monitoring system. This product concentration makes the company susceptible to market shifts, technological advancements, or any disruptions affecting these specific offerings, which could render them less competitive.
- Regulatory Challenges and FDA Scrutiny: As a manufacturer of medical devices, iRadimed operates within a stringent regulatory landscape governed by the FDA and other international bodies. Increased scrutiny on 510(k) clearances, slower approval times for new devices, changes in regulations, or issues of non-compliance could lead to costly penalties, product recalls, operational restrictions, or delays in launching new products. The company has previously received an FDA warning letter related to software updates requiring new 510(k) submissions.
- Supply Chain Vulnerabilities: iRadimed's reliance on third-party and, in some cases, single-source suppliers for critical components exposes it to potential supply chain disruptions. Such disruptions could result in manufacturing delays or interruptions, impacting the company's ability to meet customer demand and fulfill sales agreements. Global trade tensions also present a risk to the stability of its supply chain and overall input costs.
AI Analysis | Feedback
null
AI Analysis | Feedback
iRadimed (IRMD) operates in two primary addressable markets: MRI-compatible intravenous (IV) infusion pump systems and MRI-compatible patient vital signs monitoring systems.
MRI Compatible IV Infusion Pump Systems
The global market for MRI-compatible IV infusion pump systems was valued at approximately USD 381.16 million in 2025. This market is projected to grow to approximately USD 614.98 million by 2031, exhibiting a compound annual growth rate (CAGR) of 8.30% during this period. North America is a leading region in this market, holding a 44.10% share in 2025.
MRI Compatible Patient Vital Signs Monitoring Systems
The global MRI-compatible patient monitoring systems market is projected to be valued at approximately USD 4.3 billion in 2025. This market is expected to reach approximately USD 6.4 billion by 2035, growing at a CAGR of 4.0%. Another estimate places the global MRI monitoring devices market size at US$4.2 billion in 2025, anticipated to reach US$5.6 billion by 2032 with a CAGR of 4.2%. North America is identified as the largest market for MRI-compatible patient monitoring systems.
AI Analysis | Feedback
iRadimed (IRMD) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market dynamics:
- Launch and Replacement Cycle of the New 3870 MRI-Compatible IV Infusion Pump System: The company anticipates a significant increase in revenue from the introduction and widespread adoption of its next-generation 3870 MRI-compatible IV infusion pump. This new pump, with enhanced usability and technology, is expected to catalyze a major replacement cycle for existing legacy pump systems among hospitals and imaging centers, as well as attract new customers. Management is targeting a $100 million-plus annual revenue run rate in 2026, with initial shipments commencing in late 2025 and a full general sales release in April 2026, leading to significant revenue contributions in the second half of 2026.
- Growth in Patient Vital Signs Monitoring Systems and Disposables: The existing patient vital signs monitoring systems and associated disposable products are expected to continue contributing to revenue growth. The company has observed consistent gains in these product lines, with disposable revenue increasing due to higher utilization of its devices.
- International Market Expansion: iRadimed plans to expand its market presence geographically, specifically targeting Europe by the end of 2026 and Japan by the summer of 2027. This expansion into new international markets is anticipated to broaden the company's reach for its MRI-compatible infusion systems and monitoring products.
- Sustained Demand and Backlog for Legacy 3860 Pumps: Even with the introduction of the new 3870 pump, the legacy 3860 MRI-compatible infusion pump systems continue to experience strong demand. The company expects to maintain quarterly revenue in the first half of 2026, partly driven by the existing backlog of 3860 pumps.
- Higher Average Selling Price (ASP) of the 3870 Pump: The new 3870 pump is expected to command a higher average selling price compared to its predecessor. This increased pricing power for the advanced product is anticipated to directly contribute to augmented revenue.
AI Analysis | Feedback
Share Repurchases
- iRadimed reported net share repurchases of $2.6 million in 2025.
Share Issuance
- No significant share issuances were reported in the last 3-5 years; the net figure for common shares in 2025 reflected a repurchase.
Outbound Investments
- iRadimed has not completed any acquisitions in the last few years, though it evaluates such opportunities.
Capital Expenditures
- Capital expenditures for the fiscal year 2025 were approximately $7.0 million and $8.2 million in 2024, primarily related to the construction of a new corporate office building which was completed in 2025.
- In November 2022, the company acquired approximately 27 acres of land in Orlando, Florida, for $7.3 million, related to its new facility.
Peer Outperformance in Life Sciences Tools & Services
IRMD has outperformed 97% of its 108 Life Sciences Tools & Services peers over 5Y. Life Sciences Tools & Services ranks 8th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Life Sciences Tools & Services constituents that IRMD has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
65%
of 126 industry peers · 23.7% return
3Y
84%
of 116 industry peers · 145.4% return
5Y
97%
of 108 industry peers · 175.2% return
No Life Sciences Tools & Services peer with a comparable growth profile has beaten IRMD by more than 20pp over 5Y.
Median price return by industry across the Health Care sector, ranked by 5Y. Life Sciences Tools & Services is IRMD's own industry. Use this to see which corners of the sector have carried the returns.
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 13.0% | 46.4% | 96.1% | CAH 447% · MCK 381% · COR 185% |
| Health Care Services | 20 | 22.6% | 36.5% | 10.9% | HIMS 289% · RDNT 158% · DGX 81% |
| Managed Health Care | 8 | 37.5% | -6.1% | 5.7% | OSCR 137% · HQY 44% · ELV 18% |
| Health Care Facilities | 24 | 1.7% | 12.6% | 5.5% | THC 324% · NHC 267% · ENSG 140% |
| Health Care Equipment | 50 | -2.8% | 3.7% | -15.7% | POCI 11350% · UFPT 351% · GKOS 251% |
| Pharmaceuticals | 62 | -7.3% | -3.0% | -29.5% | INDV 1060% · ETON 976% · LQDA 780% |
| Health Care Supplies | 12 | 30.5% | -5.1% | -35.7% | LNTH 327% · HAE 75% · MMSI 21% |
| Life Sciences Tools & Services ← | 109 | -8.6% | -3.1% | -63.0% | SNWV 2194% · NTRA 268% · MEDP 235% |
| Biotechnology | 364 | -17.4% | -24.7% | -80.3% | DNTH 1099% · CELZ 1098% · ELVN 937% |
| Health Care Technology | 21 | -27.9% | -61.0% | -82.3% | SPOK 77% · HSTM 19% · VEEV 4% |
Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| iRadimed Earnings Notes | 12/16/2025 | |
| Can iRadimed Stock Hold Up When Markets Turn? | 10/17/2025 | |
| iRadimed Total Shareholder Return (TSR): 18.2% in 2024 and 10.7% 3-yr compounded annual returns (above peer average) | 03/07/2025 | |
| iRadimed (IRMD) Operating Cash Flow Comparison | 02/17/2025 | |
| iRadimed (IRMD) Net Income Comparison | 02/15/2025 | |
| iRadimed (IRMD) Operating Income Comparison | 02/15/2025 | |
| iRadimed (IRMD) Revenue Comparison | 02/13/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 88.01 |
| Mkt Cap | 21.2 |
| Rev LTM | 16,368 |
| Op Inc LTM | 1,484 |
| FCF LTM | 1,196 |
| FCF 3Y Avg | 1,113 |
| CFO LTM | 1,710 |
| CFO 3Y Avg | 1,559 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.1% |
| Rev Chg 3Y Avg | 6.6% |
| Rev Chg Q | 5.4% |
| QoQ Delta Rev Chg LTM | 1.2% |
| Op Inc Chg LTM | 6.6% |
| Op Inc Chg 3Y Avg | 13.7% |
| Op Mgn LTM | 13.8% |
| Op Mgn 3Y Avg | 13.3% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 14.7% |
| CFO/Rev 3Y Avg | 13.4% |
| FCF/Rev LTM | 11.8% |
| FCF/Rev 3Y Avg | 10.6% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) | 84 | 73 | 66 | ||
| Amortization of extended warranty agreements | 2 | 2 | |||
| Disposables | 15 | 13 | |||
| Ferro Magnetic Detection Systems | 0 | ||||
| Magnetic Resonance Imaging (MRI) Compatible Intravenous (IV) Infusion Pump Systems | 15 | 13 | |||
| Magnetic Resonance Imaging (MRI) Compatible Patient Vital Signs Monitoring Systems | 22 | 14 | |||
| Total | 84 | 73 | 66 | 53 | 42 |
Price Behavior
Price Behavior
| Market Price | $87.45 | |
| Market Cap ($ Bil) | 1.1 | |
| First Trading Date | 07/16/2014 | |
| Distance from 52W High | -16.4% | |
| 50 Days | 200 Days | |
| DMA Price | $86.47 | $93.09 |
| DMA Trend | indeterminate | down |
| Distance from DMA | 1.1% | -6.1% |
| 3M | 1YR | |
| Volatility | 26.6% | 30.5% |
| Downside Capture | 39.13 | 30.25 |
| Upside Capture | -21.71 | 48.18 |
| Correlation (SPY) | 6.2% | 24.2% |
IRMD Betas & Captures as of 9/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.43 | 0.60 | 0.30 | 0.45 | 0.58 | 0.74 |
| Up Beta | 0.23 | 0.81 | 0.87 | 0.82 | 0.66 | 0.80 |
| Down Beta | 1.25 | 0.08 | 0.28 | 0.20 | 0.86 | 0.69 |
| Up Capture | 34% | 38% | -10% | 15% | 44% | 51% |
| Bmk +ve Days | 6 | 16 | 27 | 66 | 132 | 424 |
| Stock +ve Days | 10 | 17 | 27 | 59 | 135 | 372 |
| Down Capture | 46% | 99% | 51% | 67% | 44% | 86% |
| Bmk -ve Days | 16 | 26 | 37 | 60 | 120 | 328 |
| Stock -ve Days | 11 | 24 | 35 | 65 | 114 | 374 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IRMD | |
|---|---|---|---|---|
| IRMD | 15.4% | 30.8% | 0.47 | - |
| Sector ETF (XLV) | 19.8% | 15.8% | 0.94 | 24.6% |
| Equity (SPY) | 16.7% | 13.0% | 0.91 | 24.4% |
| Gold (GLD) | 3.3% | 29.5% | 0.11 | 8.4% |
| Commodities (DBC) | 45.0% | 20.9% | 1.67 | -20.8% |
| Real Estate (VNQ) | 4.8% | 13.8% | 0.09 | 21.6% |
| Bitcoin (BTCUSD) | -33.2% | 44.2% | -0.79 | 8.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IRMD | |
|---|---|---|---|---|
| IRMD | 23.7% | 42.5% | 0.62 | - |
| Sector ETF (XLV) | 7.7% | 15.2% | 0.31 | 26.9% |
| Equity (SPY) | 13.9% | 17.1% | 0.62 | 35.6% |
| Gold (GLD) | 18.5% | 18.9% | 0.79 | 4.4% |
| Commodities (DBC) | 10.0% | 19.5% | 0.39 | 1.1% |
| Real Estate (VNQ) | 1.3% | 18.8% | -0.04 | 30.5% |
| Bitcoin (BTCUSD) | 11.4% | 52.0% | 0.39 | 19.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with IRMD | |
|---|---|---|---|---|
| IRMD | 18.9% | 48.0% | 0.54 | - |
| Sector ETF (XLV) | 11.0% | 16.7% | 0.53 | 24.4% |
| Equity (SPY) | 15.5% | 17.9% | 0.73 | 30.5% |
| Gold (GLD) | 11.8% | 16.4% | 0.59 | 4.0% |
| Commodities (DBC) | 8.2% | 18.1% | 0.37 | 9.0% |
| Real Estate (VNQ) | 4.5% | 20.7% | 0.18 | 26.7% |
| Bitcoin (BTCUSD) | 63.5% | 66.2% | 1.03 | 10.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 8/18/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/1/2026 | 4.4% | 4.0% | 10.6% |
| 2/10/2026 | 9.6% | 4.9% | 5.2% |
| 11/3/2025 | 9.5% | 9.8% | 21.6% |
| 8/1/2025 | 13.4% | 18.2% | 24.5% |
| 5/5/2025 | -2.2% | -3.0% | 12.2% |
| 2/13/2025 | -8.4% | -5.5% | -13.0% |
| 10/31/2024 | -6.9% | 6.2% | 2.2% |
| 8/1/2024 | -1.2% | -7.5% | 1.0% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 15 | 14 | 16 |
| # Negative | 8 | 9 | 7 |
| Median Positive | 6.9% | 5.6% | 10.0% |
| Median Negative | -3.3% | -5.5% | -7.8% |
| Max Positive | 23.7% | 28.2% | 24.5% |
| Max Negative | -20.1% | -20.7% | -19.4% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/1/2026 | 4.4% | 4.0% | 10.6% |
| 2/10/2026 | 9.6% | 4.9% | 5.2% |
| 11/3/2025 | 9.5% | 9.8% | 21.6% |
| 8/1/2025 | 13.4% | 18.2% | 24.5% |
| 5/5/2025 | -2.2% | -3.0% | 12.2% |
| 2/13/2025 | -8.4% | -5.5% | -13.0% |
| 10/31/2024 | -6.9% | 6.2% | 2.2% |
| 8/1/2024 | -1.2% | -7.5% | 1.0% |
| 5/2/2024 | 4.4% | 3.4% | 1.5% |
| 2/8/2024 | 0.0% | -1.7% | -5.2% |
| 11/3/2023 | 9.9% | -2.3% | 3.1% |
| 8/3/2023 | 10.2% | 8.9% | 5.7% |
| 5/4/2023 | 7.1% | 9.9% | 13.0% |
| 2/2/2023 | -2.1% | -16.2% | -6.3% |
| 11/3/2022 | 6.7% | 3.1% | 9.4% |
| 7/29/2022 | 6.9% | -4.7% | -17.8% |
| 4/29/2022 | -20.1% | -20.7% | -19.4% |
| 2/4/2022 | 23.7% | 28.2% | 20.3% |
| 10/29/2021 | 3.1% | 5.0% | 23.0% |
| 7/30/2021 | -2.4% | 4.6% | -2.2% |
| 4/30/2021 | 3.5% | 11.0% | 3.9% |
| 2/4/2021 | -4.3% | -5.8% | -7.8% |
| 10/30/2020 | 3.2% | 0.8% | 11.7% |
| SUMMARY STATS | |||
| # Positive | 15 | 14 | 16 |
| # Negative | 8 | 9 | 7 |
| Median Positive | 6.9% | 5.6% | 10.0% |
| Median Negative | -3.3% | -5.5% | -7.8% |
| Max Positive | 23.7% | 28.2% | 24.5% |
| Max Negative | -20.1% | -20.7% | -19.4% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 07/31/2026 | 10-Q |
| 03/31/2026 | 05/01/2026 | 10-Q |
| 12/31/2025 | 03/06/2026 | 10-K |
| 09/30/2025 | 11/03/2025 | 10-Q |
| 06/30/2025 | 08/01/2025 | 10-Q |
| 03/31/2025 | 05/05/2025 | 10-Q |
| 12/31/2024 | 03/06/2025 | 10-K |
| 09/30/2024 | 10/31/2024 | 10-Q |
| 06/30/2024 | 08/01/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 03/01/2024 | 10-K |
| 09/30/2023 | 11/03/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 03/02/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 07/31/2026 | 10-Q |
| 03/31/2026 | 05/01/2026 | 10-Q |
| 12/31/2025 | 03/06/2026 | 10-K |
| 09/30/2025 | 11/03/2025 | 10-Q |
| 06/30/2025 | 08/01/2025 | 10-Q |
| 03/31/2025 | 05/05/2025 | 10-Q |
| 12/31/2024 | 03/06/2025 | 10-K |
| 09/30/2024 | 10/31/2024 | 10-Q |
| 06/30/2024 | 08/01/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 03/01/2024 | 10-K |
| 09/30/2023 | 11/03/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 03/02/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/05/2022 | 10-Q |
| 03/31/2022 | 05/06/2022 | 10-Q |
| 12/31/2021 | 03/04/2022 | 10-K |
| 09/30/2021 | 11/05/2021 | 10-Q |
| 06/30/2021 | 08/06/2021 | 10-Q |
| 03/31/2021 | 05/07/2021 | 10-Q |
| 12/31/2020 | 03/05/2021 | 10-K |
| 09/30/2020 | 11/06/2020 | 10-Q |
| 06/30/2020 | 08/06/2020 | 10-Q |
| 03/31/2020 | 05/07/2020 | 10-Q |
| 12/31/2019 | 03/06/2020 | 10-K |
| 09/30/2019 | 11/07/2019 | 10-Q |
Recent Forward Guidance
Updated 10/4/2026Latest: Q1 2026 Earnings Reported 5/1/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q2 2026 Revenue | Reported | 20.00 Mil | 20.50 Mil | 21.00 Mil | ||||
| Q2 2026 GAAP Diluted EPS | Reported | 0.4 | 0.42 | 0.44 | ||||
| Q2 2026 Non-GAAP Diluted EPS | Reported | 0.44 | 0.46 | 0.48 | ||||
| 2026 Revenue | Reported | 91.00 Mil | 93.50 Mil | 96.00 Mil | 0 | Affirmed | Guidance: 93.50 Mil for 2026 | |
| 2026 GAAP Diluted EPS | Reported | 1.9 | 1.98 | 2.05 | 0 | 0 | Affirmed | Guidance: 1.98 for 2026 |
| 2026 Non-GAAP Diluted EPS | Reported | 2.06 | 2.14 | 2.21 | 0 | 0 | Affirmed | Guidance: 2.14 for 2026 |
Prior: Q4 2025 Earnings Reported 2/10/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2026 Revenue | Reported | 21.00 Mil | 21.50 Mil | 22.00 Mil | -1.8% | Lower New | Guidance: 21.90 Mil for Q4 2025 | |
| Q1 2026 GAAP Diluted EPS | Reported | 0.39 | 0.41 | 0.43 | -8.9% | Lower New | Guidance: 0.45 for Q4 2025 | |
| Q1 2026 Non-GAAP Diluted EPS | Reported | 0.44 | 0.46 | 0.48 | -6.1% | Lower New | Guidance: 0.49 for Q4 2025 | |
| 2026 Revenue | Reported | 91.00 Mil | 93.50 Mil | 96.00 Mil | 12.7% | Higher New | Guidance: 83.00 Mil for 2025 | |
| 2026 GAAP Diluted EPS | Reported | 1.9 | 1.98 | 2.05 | 16.2% | Higher New | Guidance: 1.7 for 2025 | |
| 2026 Non-GAAP Diluted EPS | Reported | 2.06 | 2.14 | 2.21 | 14.8% | Higher New | Guidance: 1.86 for 2025 | |
Q3 2025 Earnings Reported 11/3/2025
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q4 2025 Revenue | Reported | 21.40 Mil | 21.90 Mil | 22.40 Mil | 5.8% | Higher New | Guidance: 20.70 Mil for Q3 2025 | |
| Q4 2025 GAAP Diluted EPS | Reported | 0.43 | 0.45 | 0.47 | 2.0% | Higher New | Guidance: 0.43 for Q3 2025 | |
| Q4 2025 Non-GAAP Diluted EPS | Reported | 0.47 | 0.49 | 0.51 | 2.0% | Higher New | Guidance: 0.47 for Q3 2025 | |
| 2025 Revenue | Reported | 82.50 Mil | 83.00 Mil | 83.50 Mil | 2.2% | Raised | Guidance: 81.25 Mil for 2025 | |
| 2025 GAAP Diluted EPS | Reported | 1.68 | 1.7 | 1.72 | 5.0% | Raised | Guidance: 1.65 for 2025 | |
| 2025 Non-GAAP Diluted EPS | Reported | 1.84 | 1.86 | 1.88 | 5.0% | Raised | Guidance: 1.81 for 2025 | |
Insider Activity
Updated 9/25/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Allen, Monty K | Direct | Sell | 9082026 | 86.41 | 1,419 | 122,622 | 1,692,079 | Form | |
| 2 | Scharen-Guivel, Hilda Frederique | Direct | Sell | 6042026 | 95.00 | 3,000 | 285,000 | 531,810 | Form | |
| 3 | Susi, Roger E | CEO, President, Chairman | Phillip Susi 2008 Dynasty Trust | Sell | 6022026 | 90.60 | 2,500 | 226,507 | 195,928,702 | Form |
| 4 | Susi, Roger E | CEO, President, Chairman | Phillip Susi 2008 Dynasty Trust | Sell | 5282026 | 91.95 | 2,500 | 229,878 | 199,074,417 | Form |
| 5 | Susi, Roger E | CEO, President, Chairman | Phillip Susi 2008 Dynasty Trust | Sell | 5282026 | 92.23 | 5,000 | 461,166 | 199,915,322 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Allen, Monty K | Direct | Sell | 9082026 | 86.41 | 1,419 | 122,622 | 1,692,079 | Form | |
| 2 | Scharen-Guivel, Hilda Frederique | Direct | Sell | 6042026 | 95.00 | 3,000 | 285,000 | 531,810 | Form | |
| 3 | Susi, Roger E | CEO, President, Chairman | Phillip Susi 2008 Dynasty Trust | Sell | 6022026 | 90.60 | 2,500 | 226,507 | 195,928,702 | Form |
| 4 | Susi, Roger E | CEO, President, Chairman | Phillip Susi 2008 Dynasty Trust | Sell | 5282026 | 91.95 | 2,500 | 229,878 | 199,074,417 | Form |
| 5 | Susi, Roger E | CEO, President, Chairman | Phillip Susi 2008 Dynasty Trust | Sell | 5282026 | 92.23 | 5,000 | 461,166 | 199,915,322 | Form |
| 6 | Susi, Roger E | CEO, President, Chairman | Phillip Susi 2008 Dynasty Trust | Sell | 5202026 | 87.88 | 2,500 | 219,694 | 190,913,678 | Form |
| 7 | Susi, Roger E | CEO, President, Chairman | Phillip Susi 2008 Dynasty Trust | Sell | 5202026 | 87.51 | 5,000 | 437,571 | 190,343,511 | Form |
| 8 | Susi, Roger E | CEO, President, Chairman | Phillip Susi 2008 Dynasty Trust | Sell | 5132026 | 83.92 | 4,411 | 370,183 | 182,951,600 | Form |
| 9 | Susi, Roger E | CEO, President, Chairman | Phillip Susi 2008 Dynasty Trust | Sell | 5132026 | 84.54 | 3,089 | 261,157 | 184,679,455 | Form |
| 10 | Susi, Roger E | CEO, President, Chairman | Phillip Susi 2008 Dynasty Trust | Sell | 5062026 | 85.74 | 3,750 | 321,529 | 187,558,583 | Form |
| 11 | Susi, Roger E | CEO, President, Chairman | Phillip Susi 2008 Dynasty Trust | Sell | 5062026 | 85.69 | 3,750 | 321,333 | 187,765,478 | Form |
| 12 | Susi, Roger E | CEO, President, Chairman | Phillip Susi 2008 Dynasty Trust | Sell | 4302026 | 86.23 | 3,750 | 323,364 | 189,275,611 | Form |
| 13 | Susi, Roger E | CEO, President, Chairman | Phillip Susi 2008 Dynasty Trust | Sell | 4302026 | 89.16 | 3,750 | 334,345 | 196,037,806 | Form |
| 14 | Susi, Roger E | CEO, President, Chairman | Phillip Susi 2008 Dynasty Trust | Sell | 4212026 | 90.94 | 2,500 | 227,345 | 200,290,839 | Form |
| 15 | Susi, Roger E | CEO, President, Chairman | Phillip Susi 2008 Dynasty Trust | Sell | 4212026 | 93.36 | 5,000 | 466,779 | 205,849,627 | Form |
| 16 | Susi, Roger E | CEO, President, Chairman | Phillip Susi 2008 Dynasty Trust | Sell | 4152026 | 93.84 | 2,500 | 234,605 | 207,390,926 | Form |
| 17 | Susi, Roger E | CEO, President, Chairman | Phillip Susi 2008 Dynasty Trust | Sell | 4152026 | 92.52 | 5,000 | 462,584 | 204,693,460 | Form |
| 18 | Susi, Roger E | CEO, President, Chairman | Phillip Susi 2008 Dynasty Trust | Sell | 4072026 | 94.84 | 2,500 | 237,098 | 210,305,961 | Form |
| 19 | Susi, Roger E | CEO, President, Chairman | Phillip Susi 2008 Dynasty Trust | Sell | 4072026 | 96.02 | 5,000 | 480,110 | 213,168,640 | Form |
| 20 | Susi, Roger E | CEO, President, Chairman | Phillip Susi 2008 Dynasty Trust | Sell | 4012026 | 95.02 | 7,500 | 712,614 | 211,408,835 | Form |
| 21 | Susi, Roger E | CEO, PRESIDENT, CHAIRMAN | Phillip Susi 2008 Dynasty Trust | Sell | 3252026 | 100.28 | 2,500 | 250,697 | 223,872,600 | Form |
| 22 | Susi, Roger E | CEO, PRESIDENT, CHAIRMAN | Phillip Susi 2008 Dynasty Trust | Sell | 3252026 | 100.38 | 5,000 | 501,912 | 224,354,664 | Form |
| 23 | Susi, Roger E | CEO, PRESIDENT, CHAIRMAN | Phillip Susi 2008 Dynasty Trust | Sell | 3182026 | 102.43 | 2,500 | 256,075 | 229,443,200 | Form |
| 24 | Susi, Roger E | CEO, PRESIDENT, CHAIRMAN | Phillip Susi 2008 Dynasty Trust | Sell | 3182026 | 101.38 | 5,000 | 506,895 | 227,342,632 | Form |
| 25 | Susi, Roger E | CEO, PRESIDENT, CHAIRMAN | Phillip Susi 2008 Dynasty Trust | Sell | 3092026 | 98.39 | 7,500 | 737,919 | 221,867,646 | Form |
| 26 | Allen, Monty K | Direct | Sell | 2132026 | 100.26 | 1,000 | 100,256 | 2,105,382 | Form | |
| 27 | Susi, Roger E | CEO, PRESIDENT, CHAIRMAN | Phillip Susi 2008 Dynasty Trust | Sell | 1272026 | 100.65 | 5,000 | 503,255 | 227,722,996 | Form |
| 28 | Susi, Roger E | CEO, PRESIDENT, CHAIRMAN | Phillip Susi 2008 Dynasty Trust | Sell | 1212026 | 101.84 | 5,000 | 509,225 | 230,933,533 | Form |
| 29 | Susi, Roger E | CEO, PRESIDENT, CHAIRMAN | Phillip Susi 2008 Dynasty Trust | Sell | 1132026 | 97.45 | 5,000 | 487,231 | 221,446,326 | Form |
| 30 | Susi, Roger E | CEO, PRESIDENT, CHAIRMAN | Phillip Susi 2008 Dynasty Trust | Sell | 1062026 | 97.68 | 5,000 | 488,417 | 222,474,062 | Form |
| 31 | Susi, Roger E | CEO, PRESIDENT, CHAIRMAN | Phillip Susi 2008 Dynasty Trust | Sell | 12302025 | 97.66 | 5,000 | 488,317 | 222,916,555 | Form |
| 32 | Susi, Roger E | CEO, PRESIDENT, CHAIRMAN | Phillip Susi 2008 Dynasty Trust | Sell | 12222025 | 96.73 | 5,000 | 483,672 | 221,279,867 | Form |
| 33 | Susi, Roger E | CEO, PRESIDENT, CHAIRMAN | Phillip Susi 2008 Dynasty Trust | Sell | 12172025 | 96.75 | 5,000 | 483,729 | 221,789,724 | Form |
| 34 | Glenn, John | CHIEF FINANCIAL OFFICER | Direct | Sell | 12122025 | 97.29 | 15,000 | 1,459,342 | 716,245 | Form |
| 35 | Hawkins, James B | Direct | Sell | 12102025 | 96.61 | 3,000 | 289,838 | 2,776,836 | Form | |
| 36 | Susi, Roger E | CEO, PRESIDENT, CHAIRMAN | Phillip Susi 2008 Dynasty Trust | Sell | 12092025 | 95.43 | 5,000 | 477,163 | 219,256,564 | Form |
| 37 | Susi, Roger E | CEO, PRESIDENT, CHAIRMAN | Phillip Susi 2008 Dynasty Trust | Sell | 12022025 | 92.76 | 5,000 | 463,794 | 213,577,192 | Form |
| 38 | Susi, Roger E | CEO, PRESIDENT, CHAIRMAN | Phillip Susi 2008 Dynasty Trust | Sell | 11242025 | 90.36 | 5,000 | 451,814 | 208,512,327 | Form |
| 39 | Hawkins, James B | Direct | Sell | 11212025 | 88.24 | 3,000 | 264,717 | 2,695,255 | Form | |
| 40 | Susi, Roger E | CEO, PRESIDENT, CHAIRMAN | Phillip Susi 2008 Dynasty Trust | Sell | 11192025 | 85.59 | 5,000 | 427,957 | 197,930,242 | Form |
| 41 | Susi, Roger E | CEO, PRESIDENT, CHAIRMAN | Phillip Susi 2008 Dynasty Trust | Sell | 11122025 | 85.24 | 5,000 | 426,193 | 197,540,289 | Form |
| 42 | Glenn, John | CHIEF FINANCIAL OFFICER | Direct | Sell | 11122025 | 84.51 | 10,651 | 900,162 | 211,286 | Form |
| 43 | Susi, Roger E | CEO, PRESIDENT, CHAIRMAN | Phillip Susi 2008 Dynasty Trust | Sell | 11042025 | 82.64 | 5,000 | 413,216 | 191,938,832 | Form |
| 44 | Susi, Roger E | CEO, PRESIDENT, CHAIRMAN | Phillip Susi 2008 Dynasty Trust | Sell | 10272025 | 77.69 | 5,000 | 388,429 | 180,813,923 | Form |
| 45 | Susi, Roger E | CEO, PRESIDENT, CHAIRMAN | Phillip Susi 2008 Dynasty Trust | Sell | 10212025 | 74.82 | 5,000 | 374,081 | 174,508,828 | Form |
| 46 | Susi, Roger E | CEO, PRESIDENT, CHAIRMAN | Phillip Susi 2008 Dynasty Trust | Sell | 10142025 | 72.59 | 5,000 | 362,964 | 169,685,778 | Form |
| 47 | Susi, Roger E | CEO, PRESIDENT, CHAIRMAN | Phillip Susi 2008 Dynasty Trust | Sell | 10072025 | 71.72 | 5,000 | 358,614 | 168,010,659 | Form |
| 48 | Susi, Roger E | CEO, PRESIDENT, CHAIRMAN | Phillip Susi 2008 Dynasty Trust | Sell | 10022025 | 70.19 | 5,000 | 350,957 | 164,774,382 | Form |
| 49 | Susi, Roger E | CEO, PRESIDENT, CHAIRMAN | Phillip Susi 2008 Dynasty Trust | Sell | 9242025 | 71.26 | 5,000 | 356,290 | 167,634,680 | Form |
| 50 | Susi, Roger E | CEO, PRESIDENT, CHAIRMAN | Phillip Susi 2008 Dynasty Trust | Sell | 9182025 | 71.27 | 5,000 | 356,367 | 168,027,155 | Form |
Investor Activity (13F)
Updated Oct 12, 202613F holdings as of Mar 31, 2026 (Q1 2026)
Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager |
|---|
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Life Sciences Tools & Services Resources |
| GenomeWeb |
| BioSpace |
| The Scientist |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 10/11/2026